Kelly Chen

Kelly Chen is a Research Scientist at Iambic Therapeutics since March 2022, previously serving as a Research Associate II at The Janssen Pharmaceutical Companies of Johnson & Johnson from March 2020 to March 2022, and at Halozyme Therapeutics, Inc. from October 2015 to January 2020. At Halozyme, Kelly Chen conducted cell-based and biochemical assays focused on the effects of investigational drugs on hyaluronan and was involved in preclinical oncology studies. Kelly Chen also interned at Halozyme Therapeutics in mid-2014, performing similar assays and presenting findings. Educational qualifications include a Bachelor of Science in Molecular, Cell, and Developmental Biology from UCLA.